A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older Participants (60 to 79 Years Inclusive).

A Phase 1 clinical trial, NCT06630117, is being conducted to evaluate the safety, tolerability, and immunogenicity of a new vaccine, V330, in healthy younger (18 to 49 years) and healthy older (60 to 79 years) participants. The study aims to assess the body's immune response by measuring antibody production post-vaccination. The trial involves various dose escalation panels and is currently recruiting participants in the United States. The primary completion date is set for July 30, 2025, with a total enrollment target of 170 individuals. [Extracted from the article]